GALNT6 drives lenvatinib resistance in hepatocellular carcinoma through autophagy and cancer-associated fibroblast activation
Cellular Oncology · 2024
DOI: 10.1007/s13402-024-01032-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Oncology, 2024. Verfasst von Peiling Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Drug Resistance, Neoplasm, Autophagy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Natural Science Foundation of China, the Leading Project of the Science and Technology Committee of Shanghai Municipality, the Project of Shanghai Municipal Health Commission.
Abstract (Originalsprache)
BACKGROUND: Hepatocellular carcinoma (HCC) remains a significant global health challenge with limited treatment options. Lenvatinib, a tyrosine kinase inhibitor, has shown promise but is often undermined by the development of drug resistance. METHODS: Utilizing high-throughput sequencing, we investigated the molecular mechanisms underlying lenvatinib resistance in HCC cells, with a focus on metabolic pathways. Key genes, including GALNT6, were validated through quantitative real-time PCR. The effects of GALNT6 knockdown on lenvatinib sensitivity were examined in vitro and in vivo. O-GalNAc glycosylation was assessed using Vicia Villosa Lectin. Immune cell infiltration and interactions were analyzed in the TCGA-LIHC cohort, with further validation by Western blotting and immunohistochemistry. RESULTS: Our findings indicate that lenvatinib resistance in HCC is driven by the mucin-type O-glycosylation pathway, with GALNT6 playing a critical role. Knockdown of GALNT6 led to reduced O-GalNAc glycosylation, including the modification of LAPTM5, resulting in decreased LAPTM5 activity and autophagy inhibition. Additionally, GALNT6 silencing disrupted the PDGFA-PDGFRB axis, impairing the activation of cancer-associated fibroblasts (CAFs) and reducing their secretion of SPP1, which collectively diminished lenvatinib resistance. CONCLUSIONS: GALNT6 is integral to the resistance mechanisms against lenvatinib in HCC by modulating autophagy and CAF activation. Targeting GALNT6 offers a promising strategy to enhance lenvatinib efficacy and improve therapeutic outcomes in HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
- Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Fudan University, Shanghai, 200032, China.
- Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, China.
- Research Unit of Liver Cancer Recurrence and Metastasis, Chinese Academy of Medical Sciences, Beijing, China.
- Departments of Radiation Oncology Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. transplant@126.com.
Förderung
- Natural Science Foundation of China
- the Leading Project of the Science and Technology Committee of Shanghai Municipality
- the Project of Shanghai Municipal Health Commission
Zitieren
APA
Zhang, P., Chen, S., Cai, J., Song, L., Quan, B., Wan, J., Zhu, G., Wang, B., Yang, Y., Zhou, Z., Li, T., & Dai, Z. (2024). GALNT6 drives lenvatinib resistance in hepatocellular carcinoma through autophagy and cancer-associated fibroblast activation. Cellular Oncology. https://doi.org/10.1007/s13402-024-01032-7
Vancouver
Zhang P, Chen S, Cai J, Song L, Quan B, Wan J, et al. GALNT6 drives lenvatinib resistance in hepatocellular carcinoma through autophagy and cancer-associated fibroblast activation. Cellular Oncology. 2024. doi:10.1007/s13402-024-01032-7
BibTeX
@article{Zhang2024,
author = {Zhang, Peiling and Chen, Shiping and Cai, Jialiang and Song, Lina and Quan, Bing and Wan, Jinglei and Zhu, Guiqi and Wang, Biao and Yang, Yi and Zhou, Zhengjun and Li, Tao and Dai, Zhi},
title = {GALNT6 drives lenvatinib resistance in hepatocellular carcinoma through autophagy and cancer-associated fibroblast activation},
journal = {Cellular Oncology},
year = {2024},
doi = {10.1007/s13402-024-01032-7}
}
EUVIMED